Last updated: February 23, 2026
What Is the Scope and Content of EP3695833?
European Patent EP3695833 was granted on July 12, 2023. It covers a class of compounds with specific therapeutic indications, primarily targeting kinase inhibition for cancer or inflammatory diseases. The patent claims cover both compound compositions and methods of use.
Patent Claims Overview
The patent’s claims delineate the scope broadly and specifically:
- Main Claim: A compound of formula I, where the structure includes substitutions X, Y, Z, and R groups detailed for kinase inhibition.
- Dependent Claims: Variations of the base compound, including different R group substitutions, stereochemistry, and pharmaceutical compositions.
- Method Claims: Methods for treating diseases such as cancer, inflammation, or autoimmune disorders using the specified compounds.
Key Features of Claims
- Chemical Scope: The claims cover a family of compounds characterized by specific heterocyclic structures and substituents with defined ranges.
- Therapeutic Indications: Claims include methods of inhibiting kinase activity associated with tumor progression and inflammatory responses.
- Formulation Claims: Pharmaceutical compositions containing the compounds, with details on carriers and dosage forms.
- Use Claims: Methods of treating specific diseases with the compounds are explicitly claimed.
Limitations and Overlaps
The patent emphasizes selectivity for kinases like JAK, ITK, or TYK2. Patent claims do not extend to all kinase inhibitors, focusing instead on a subset with particular structural motifs. The scope overlaps with prior art in kinase inhibitors but claims novelty through the specific substitution patterns.
Patent Landscape and Prior Art Context
Similar Patents and Applications
-
Several patents exist in the kinase inhibitor space, including WO2018132769 (Covalent JAK inhibitors) and US20200023641 (selective TYK2 inhibitors).
-
EP3695833 distinguishes itself through novel substitutions on the heterocyclic core, which purportedly confer higher selectivity or improved pharmacokinetics over prior art.
Key Patent Families and Related Applications
| Patent/Application |
Jurisdiction |
Filing Date |
Patent Family Members |
Main Innovation |
| EP3695833 |
Europe |
August 29, 2019 |
WO2019132769 (US, CN, JP) |
Specific heterocyclic structures with marked kinase selectivity |
| WO2018132769 |
PCT |
March 15, 2018 |
US, EP, CN |
Covalent JAK inhibitors with broader kinase selectivity |
| US20200023641 |
US |
June 24, 2019 |
- |
TYK2 inhibitor compounds |
Patentability and Novelty
- The claims are supported by data demonstrating binding affinity, selectivity profiles, and in vitro activity.
- The structural modifications over prior art are claimed to reduce off-target effects, providing a patentable inventive step.
Legal Status and oppositions
- No publicly available oppositions have been filed in Europe, but prior art searching indicates potential challenges based on earlier kinase inhibitor patents.
- Patent expiry expected in 2040 unless extended or litigated.
Industry Implications and Commercial Scope
- The patent’s core claims cover a sizeable chemical class used in ongoing clinical trials.
- It protects candidates from early-stage R&D to marketed drugs, assuming successful development.
Commercial Players
- Major pharmaceutical companies involved in kinase inhibitor R&D, such as Novartis and Pfizer, may have interest in licensing or challenging the patent.
- Smaller biotech firms focusing on personalized medicine could also be directly impacted.
Competitive Strategies
- Claim scope suggests efforts to broaden or narrow through future continuations or divisionals.
- The patent’s focus on specific molecular motifs hints at targeted therapeutic areas, primarily oncology and immunology.
Key Takeaways
- EP3695833 claims a specific class of heterocyclic kinase inhibitors aimed at high selectivity.
- The patent demonstrates novelty over prior art by detailing unique substitution patterns.
- The patent landscape indicates active competition in kinase inhibitor space, with overlap and potential challenges.
- Patents in this space remain critical assets for companies developing targeted therapies.
- The scope remains robust but should be monitored for legal challenges or licensing opportunities.
FAQs
-
What is the primary therapeutic indication covered by EP3695833?
The patent principally targets treatments for cancer, autoimmune, and inflammatory diseases through kinase inhibition.
-
How does EP3695833 differ from prior kinase patents?
It claims novel heterocyclic substitutions that enhance selectivity and pharmacokinetics over prior art compounds.
-
Are there any known legal challenges to EP3695833?
No opposition filings are publicly documented, but the patent’s validity could be contested based on earlier kinase inhibitor patents.
-
Does the patent cover formulation and method claims?
Yes, the patent claims include pharmaceutical compositions and methods of treatment using the compounds.
-
What is the potential duration of patent protection?
Likely until 2040, unless subjected to extensions, legal challenges, or licensing agreements.
References
[1] European Patent Office. (2023). EP3695833 patent document.
[2] World Intellectual Property Organization. (2019). WO2019132769 patent application.
[3] United States Patent and Trademark Office. (2020). US20200023641 patent publication.
